A Study of NDV-01 (Sustained-release Gemcitabine-docetaxel) in Participants With Non-muscle Invasive Bladder Cancer
Bladder (Urothelial, Transitional Cell) Cancer · Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive) · Urothelial Carcinoma Bladder · Urothelial Carcinoma Recurrent · Urologic Cancer
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 393 (planned)
- Started
- Feb 2027
- Main results expected
- Dec 2029
- Fully finished
- Dec 2032
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Disease Free Survival in participants with Intermediate Risk NMIBC
Measured over: From date of randomization to at least 2 years of follow-up assessing for DFS events.
To evaluate the efficacy of NDV-01 (determined by complete response [CR] anytime) administered by intravesical instillation in patients with BCG-unresponsive NMIBC who have recurred after first-line intravesical therapy (approved or in development).
Measured over: From date of randomization through 3 years of follow-up assessing for CR.
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07464145 · record last updated 2026-09-02 · checked 2026-11-09 15:42 UTC